First International Prescription Drug Labeling Conference Features FDA, HEALTH CANADA, BfArM, AND PMDA

Share Article

Explore the most pressing issues facing professionals from biopharmaceutical companies, CROs, consulting agencies, and regulatory authorities involved in labeling, clinical safety, regulatory affairs, clinical research and development, and quality control.

The Drug Information Association (DIA) will host US and International Prescription Drug Labeling Comparisons and Important Updates: from December 7-9, 2010 in Washington, DC.

This first of its kind conference will explore the most pressing issues facing professionals from biopharmaceutical companies, CROs, consulting agencies, and regulatory authorities involved in labeling, clinical safety, regulatory affairs, clinical research and development, and quality control. Session topics will include:

  •     High Level Comparison of the Approaches to Prescription Drug Labeling and the Dissemination of Related Regulatory Information: Canada, European Union, Japan, and USA
  •     Important Labeling News and Developments: USA
  •     Comparative Review of the Indications and Clinical Studies Sections: Canada, European Union, Japan and United States
  •     Comparative Review of the Adverse Reactions Section: Canada, European Union, Japan and United States
  •     Comparative Review of the Warnings and Precautions, Contraindications, and Boxed Warnings Sections: Canada, European Union, Japan and United States
  •     Comparative Review of the Interactions Section: Canada, European Union, Japan, and USA
  •     Comparative Review of Approaches to Patient Information: Canada, European Union, Japan, and USA

Preconference tutorials will provide intense instruction on:

  •     The EU PIM System (Product Information Management System) from a Practical Regulatory Perspective
  •     Structured Product Labeling and eList
  •     Writing the Highlights Section of US Prescribing Information
  •     Writing the Boxed Warning, Contraindications, Warnings and Precautions and Adverse Reactions sections of US Prescribing Information

“Regulatory authorities from different regions will discuss issues commonly encountered by industry in an effort to advance understanding of labeling requirements across various regions,” says Steven W. Bass, PhD, President, Bass BioPharm Consulting Group, LLC.

Register for the US and International Prescription Drug Labeling Conference.

ABOUT THE DRUG INFORMATION ASSOCIATION (DIA)
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the life cycle management of pharmaceuticals, biotechnology, medical devices, and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies, and services to improve health and well-being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Joe Krasowski
Visit website